Multimerization domains for antibody phage display and antibody production
High-throughput generation of antibodies for proteome research has become feasible by using antibody gene libraries and in vitro selection methods like phage display. Typically monovalent antibody fragments like scFv, Fab or scFab are obtained by this technology. To mimic the IgG molecule and gain avidity, resulting in stronger binding, multimerization domains can be fused to antibody fragments. Here we systematically analyzed different multimerization domains in respect to three key parameters, crucial for the high-throughput generation of binders. (i) The compatibility to be displayed on phage (assessed for at least three different antibody formats, scFv, Fab and scFab) in combination with five different multimerization domains; (ii) production yields and (iii) oligomerization properties were analyzed for three different scFv fragments. We found that the use of a biotin acceptor domain in combination with an in vivo biotinylation system performed best concerning the key parameters and thus would be a useful tool to generate multimeric antibody complexes on demand from phage display selected antibody fragments with the least effort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2009 |
|---|---|
| Erschienen: |
2009 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
New biotechnology - 26(2009), 6 vom: 31. Dez., Seite 314-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Thie, H [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9013-20-1 |
|---|
| Anmerkungen: |
Date Completed 12.05.2010 Date Revised 30.11.2009 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nbt.2009.07.005 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM190227303 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM190227303 | ||
| 003 | DE-627 | ||
| 005 | 20231223185003.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231223s2009 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nbt.2009.07.005 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0634.xml |
| 035 | |a (DE-627)NLM190227303 | ||
| 035 | |a (NLM)19631299 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Thie, H |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Multimerization domains for antibody phage display and antibody production |
| 264 | 1 | |c 2009 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2010 | ||
| 500 | |a Date Revised 30.11.2009 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a High-throughput generation of antibodies for proteome research has become feasible by using antibody gene libraries and in vitro selection methods like phage display. Typically monovalent antibody fragments like scFv, Fab or scFab are obtained by this technology. To mimic the IgG molecule and gain avidity, resulting in stronger binding, multimerization domains can be fused to antibody fragments. Here we systematically analyzed different multimerization domains in respect to three key parameters, crucial for the high-throughput generation of binders. (i) The compatibility to be displayed on phage (assessed for at least three different antibody formats, scFv, Fab and scFab) in combination with five different multimerization domains; (ii) production yields and (iii) oligomerization properties were analyzed for three different scFv fragments. We found that the use of a biotin acceptor domain in combination with an in vivo biotinylation system performed best concerning the key parameters and thus would be a useful tool to generate multimeric antibody complexes on demand from phage display selected antibody fragments with the least effort | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies |2 NLM | |
| 650 | 7 | |a Antigens |2 NLM | |
| 650 | 7 | |a Immunoglobulin Variable Region |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Peptide Library |2 NLM | |
| 650 | 7 | |a Streptavidin |2 NLM | |
| 650 | 7 | |a 9013-20-1 |2 NLM | |
| 700 | 1 | |a Binius, S |e verfasserin |4 aut | |
| 700 | 1 | |a Schirrmann, T |e verfasserin |4 aut | |
| 700 | 1 | |a Hust, M |e verfasserin |4 aut | |
| 700 | 1 | |a Dübel, S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t New biotechnology |d 2008 |g 26(2009), 6 vom: 31. Dez., Seite 314-21 |w (DE-627)NLM179798081 |x 1876-4347 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2009 |g number:6 |g day:31 |g month:12 |g pages:314-21 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nbt.2009.07.005 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2009 |e 6 |b 31 |c 12 |h 314-21 | ||